Literature DB >> 24403442

The key role of bisphosphonates in the supportive care of cancer patients.

Maria Tolia1, Anna Zygogianni, John R Kouvaris, Christos Meristoudis, Niki Margari, Petros Karakitsos, Ioannis Kokakis, Dimitrios Kardamakis, Christos Papadimitriou, Kyriaki Mystakidou, Nikolaos Tsoukalas, George Kyrgias, Basil Armonis, Dimitrios K Filippiadis, Alexios D Kelekis, Nikolaos Kelekis, Vasileios Kouloulias.   

Abstract

UNLABELLED: The present review aims at providing an assessment of the clinical significance of Biphosphonates (BPs) in the treatment of patients with cancer.
MATERIALS AND METHODS: A systematic literature review was performed based on database search in PubMed/Medline and included articles up to August 2013.
RESULTS: BPs can reduce, delay, and prevent complications related to bone metastases. They improve mobility, functionality, pain, and quality of life. They limit survival of any inactive cancer cells in the microenvironment of the bone marrow, contributing to their death from anti-neoplastic treatments. Moreover, they limit and delay bone morbidity due to osteoporosis related to hormonotherapy in breast and prostate cancer. Finally, benefits can be derived from the combination of BPs with radiotherapy in bone density, recalcification, opioid use, and patient's quality of life and performance status.
CONCLUSION: The contribution of BPs in the course of certain neoplasms is preventive and synergistic to other treatments.

Entities:  

Keywords:  Bisphosphonates; bone metastasis; cancer; prevention; radiotherapy; review

Mesh:

Substances:

Year:  2014        PMID: 24403442

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.

Authors:  Rafael Scaf de Molon; Hiroaki Shimamoto; Olga Bezouglaia; Flavia Q Pirih; Sarah M Dry; Paul Kostenuik; Rogely W Boyce; Denise Dwyer; Tara L Aghaloo; Sotirios Tetradis
Journal:  J Bone Miner Res       Date:  2015-05-27       Impact factor: 6.741

2.  [Side effects of pain therapy : Sufficient analgesia without unnecessary complications].

Authors:  F Greul; A Zimmer; W Meißner
Journal:  Urologe A       Date:  2017-04       Impact factor: 0.639

3.  NGF blockade at early times during bone cancer development attenuates bone destruction and increases limb use.

Authors:  Gwen McCaffrey; Michelle L Thompson; Lisa Majuta; Michelle N Fealk; Stephane Chartier; Geraldine Longo; Patrick W Mantyh
Journal:  Cancer Res       Date:  2014-10-06       Impact factor: 12.701

Review 4.  Prevention and treatment of bone fragility in cancer patient.

Authors:  Silva Ottanelli
Journal:  Clin Cases Miner Bone Metab       Date:  2015-10-26

5.  IGF-1 regulates Cyr61 induced breast cancer cell proliferation and invasion.

Authors:  Suren Sarkissyan; Marianna Sarkissyan; Yanyuan Wu; Jessica Cardenas; H Phillip Koeffler; Jaydutt V Vadgama
Journal:  PLoS One       Date:  2014-07-25       Impact factor: 3.240

6.  Relations Between Bone Quantity, Microarchitecture, and Collagen Cross-links on Mechanics Following In Vivo Irradiation in Mice.

Authors:  Megan M Pendleton; Shannon R Emerzian; Saghi Sadoughi; Alfred Li; Jennifer W Liu; Simon Y Tang; Grace D O'Connell; Jean D Sibonga; Joshua S Alwood; Tony M Keaveny
Journal:  JBMR Plus       Date:  2021-09-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.